Outcomes improved with early concurrent immunotherapy and SRS in melanoma brain metastases

Specialists have reported significantly improved overall survival and distant brain failure-free survival in melanoma patients with brain metastases treated with early concurrent immunotherapy and stereotactic radiosurgery (SRS).

At the SNO 2020 virtual conference, Dr Alexander Augustyn from the University of Texas MD Andersen Cancer Center, in Houston, USA, presented data from a retrospective review of concurrent immunotherapy and SRS. Concurrent use was defined as SRS being performed within 30 days of immune checkpoint inhibitor (ICI) therapy.